Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib - Heidler, Christopher L.; Roth, Eva Kathrin; Thiemann, Markus; Blattmann, Claudia; Lopez Perez, Ramon; Huber, Peter E.; Kovac, Michal; Amthor, Beate; Neu-Yilik, Gabriele; Kulozik, Andreas (International journal of cancer, 2019)
Gesehen am 28.05.2020